Scientific Sources
We work from peer-reviewed literature, clinical consensus, and authoritative bodies.
This page has been written and edited by the publisher. It has not been reviewed by a licensed clinician.
Journals we cite frequently
- New England Journal of Medicine
- JAMA Psychiatry
- American Journal of Psychiatry
- Biological Psychiatry
- Neuropsychopharmacology
- Molecular Psychiatry
Consensus and regulatory
- APA Consensus Statement on Ketamine for Treatment-Resistant Depression (2017)
- ASKP clinical practice resources
- AAPM/ASRA consensus on IV ketamine for chronic pain (2018)
- FDA esketamine (Spravato) labeling and REMS documentation
Research programs
- Yale Depression Research Program
- NIMH Experimental Therapeutics Branch
- Mass General Hospital Ketamine Program
- Johns Hopkins Center for Psychedelic and Consciousness Research
Related reading
Educational content only. Not medical advice. Discuss any treatment decisions with a qualified clinician.
Publisher and editor of Ketalux, based in Chicago, Illinois. Ira is a ketamine therapy patient, not a clinician. This is editorial review, not medical review: Ira is not a licensed clinician and does not provide diagnosis or medical care. Ketalux does not accept compensation from providers in exchange for favorable editorial coverage, evidence ratings, recommendations, patient referrals, or organic provider ranking. Read the full publisher disclosure →
Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.